Ligand Pharmaceuticals has purchased certain intellectual property and interests in future milestones and royalties for MEDI-528, an IL-9 antibody program under development by MedImmune, an AstraZeneca subsidiary. MEDI-528 is currently in a Phase II study for moderate-to-severe asthma. Ligand paid $2.8 million to the Genaera Liquidating Trust in connection with the purchase. As part of this transaction, Ligand entered into a separate agreement with Biotechnology Value Fund, L.P. (BVF), whereb...